The examples of NfL, polyQ-ATXN3, and the pons atrophy in SCA3, together with frataxin in Friedreich’s ataxia, illustrate how well-validated biomarkers can effectively bridge mechanistic insight and trial implementation. The gene discussed is ATXN3; the disease is Friedreich ataxia.